Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Brown

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 10, 2008
Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituentAlan Brown, Lindsay Brown, T Bruce Brown, et al.
Advances in Therapy|June 11, 2024
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate CancerAshley Ross, Kelsie Brewer, Stacie Hudgens, et al.
Advances in Therapy|September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate CancerNeal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Journal of Medical Economics|August 30, 2016
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerMarjan Massoudi, Mark Balk, Hongbo Yang, et al.
Targeted Oncology|April 15, 2023
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate CancerJose De La Cerda, Curtis Dunshee, Lawrence Gervasi, et al.
Journal of Neurochemistry|October 13, 2005
Carboxypeptidase E is required for normal synaptic transmission from photoreceptors to the inner retinaXuemei Zhu, Kebin Wu, Lawrence Rife, et al.
Cancers|October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate CancerFred Saad, Daniel J George, Michael S Cookson, et al.
Clinical Genitourinary Cancer|April 16, 2023
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate CancerDaniel J George, Fred Saad, Michael S Cookson, et al.
European Urology Oncology|December 24, 2023
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyRonald Tutrone, Fred Saad, Daniel J George, et al.
Future Oncology (London, England)|August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and researchDavid F Penson, Daniel W Lin, Lawrence Karsh, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|September 10, 2008
Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituentAlan Brown, Lindsay Brown, T Bruce Brown, et al.
Advances in Therapy|June 11, 2024
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate CancerAshley Ross, Kelsie Brewer, Stacie Hudgens, et al.
Advances in Therapy|September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate CancerNeal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Journal of Medical Economics|August 30, 2016
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerMarjan Massoudi, Mark Balk, Hongbo Yang, et al.
Targeted Oncology|April 15, 2023
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate CancerJose De La Cerda, Curtis Dunshee, Lawrence Gervasi, et al.
Journal of Neurochemistry|October 13, 2005
Carboxypeptidase E is required for normal synaptic transmission from photoreceptors to the inner retinaXuemei Zhu, Kebin Wu, Lawrence Rife, et al.
Cancers|October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate CancerFred Saad, Daniel J George, Michael S Cookson, et al.
Clinical Genitourinary Cancer|April 16, 2023
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate CancerDaniel J George, Fred Saad, Michael S Cookson, et al.
European Urology Oncology|December 24, 2023
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyRonald Tutrone, Fred Saad, Daniel J George, et al.
Future Oncology (London, England)|August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and researchDavid F Penson, Daniel W Lin, Lawrence Karsh, et al.
Pageof 4